Estados financieros detallados de Acurx Pharmaceuticals, Inc. (ACXP): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.38, ACXP presenta beneficios negativos (P/E no significativo) y un ROE del -124.74%. La capitalización bursátil es de $6M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $3.5M | $2.2M | $2.0M | $4.8M | $6.0M | $5.4M | $1.83B |
| Generales y Administrativos | $2.4M | $2.4M | $10.8M | $7.3M | $8.5M | $8.7M | $6.26B |
| Gastos Operativos | $5.9M | $4.6M | $12.8M | $12.1M | $14.6M | $14.1M | $8.1M |
| Beneficio Operativo | -$5.9M | -$4.6M | -$12.8M | -$12.1M | -$14.6M | -$14.1M | -$8.1M |
| EBITDA | 0 | 0 | -$12.7M | -$12.1M | -$14.6M | 0 | -$8.0M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| BPA | $-12.00 | $-9.28 | $-24.96 | $-22.36 | $-23.01 | $-17.59 | $-5.32 |
| BPA Diluido | $-12.00 | $-9.28 | $-24.96 | $-22.36 | $-23.01 | $-17.59 | $-5.32 |
| Acciones en Circulación (Diluidas) | $477050 | $495800 | $510800 | $540800 | $633600 | $851550 | $1.5M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 |
| Beneficio Operativo | -$2.0M | -$1.6M | -$1.7M | -$2.3M |
| EBITDA | -$2.0M | -$1.6M | -$1.7M | -$2.3M |
| Beneficio Neto | -$2.0M | -$1.6M | -$1.7M | -$2.3M |
| BPA | $-1.23 | $-0.67 | $-1.12 | $-0.53 |
| BPA Diluido | $-1.23 | $-0.67 | $-1.12 | $-0.53 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $2.5M | $3.2M | $13.0M | $9.1M | $7.5M | $3.7M | $7.6M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | $129159 | $51127 | $48417 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $2.5M | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M |
| Inmovilizado Material | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $2.5M | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M |
| Cuentas por Pagar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deuda a Corto | 0 | $16625 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $1.7M | $472556 | $843909 | $2.1M | $3.0M | $3.2M | $2.4M |
| Deuda a Largo | 0 | $49878 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $1.7M | $522434 | $843909 | $2.1M | $3.0M | $3.2M | $2.4M |
| Reservas | -$9.2M | -$13.8M | -$26.5M | -$38.6M | -$53.2M | -$67.3M | -$75.3M |
| Patrimonio Neto | $819854 | $2.7M | $12.4M | $7.3M | $4.7M | $615121 | $5.3M |
| Deuda Total | 0 | $66503 | 0 | 0 | 0 | 0 | 0 |
| Deuda Neta | -$2.5M | -$3.1M | -$13.0M | -$9.1M | -$7.5M | -$3.7M | -$7.6M |
| Capital Circulante | $819854 | $2.8M | $12.4M | $7.3M | $4.7M | $615121 | $5.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $5.9M | $7.6M | $9.3M | $10.7M |
| Activos Totales | $6.1M | $7.7M | $9.5M | $11.0M |
| Pasivos Totales | $2.5M | $2.4M | $2.5M | $2.8M |
| Patrimonio Neto | $3.6M | $5.3M | $7.0M | $8.2M |
| Deuda Total | 0 | 0 | 0 | 0 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| Amortizaciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $900431 | $1.3M | $6.7M | $3.3M | $3.8M | $3.4M | $1.6M |
| Cambio en Capital Circulante | $1.0M | -$801166 | $141283 | $1.2M | $1.0M | $284089 | -$390964 |
| Flujo de Caja Operativo | -$4.0M | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | -$1040 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$4.0M | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$1.9M | -$1.2M | -$1.4M | -$1.7M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.9M | -$1.2M | -$1.4M | -$1.7M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $339852 | $375794 | $319287 | 0 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | +22.4% | -177.1% | +5.1% | -20.5% | +3.3% | +43.5% |
| Crecimiento BPA (anual) | | +22.7% | -169.0% | +10.4% | -2.9% | +23.6% | +69.8% |
| Cambio en Acciones (anual) | | +3.9% | +3.0% | +5.9% | +17.2% | +34.4% | +76.0% |
| Crecimiento FCF (anual) | | +15.9% | -49.6% | -50.4% | -29.9% | -5.9% | +34.6% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-8.35 | $-6.76 | $-9.82 | $-13.95 | $-15.47 | $-12.19 | $-4.53 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $375100 | $495800 | $510800 | $540800 | $633600 | $851550 | $1.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -124.74% |
| Rentabilidad sobre capital invertido | -94.08% |
| Rentabilidad sobre activos | -68.33% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 3.88 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -13.15 | -17.00 | -3.46 | -3.56 | -3.33 | -0.93 | -0.47 |
| P/VC | 72.20 | 28.96 | 3.56 | 5.88 | 10.40 | 22.54 | 0.71 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |